Tagged with B

Saudi Arabia Boehringer Ingelheim’s Regional Managing Director and Head of Human Pharma in the Middle East, Turkey, and Africa (‘META’) Mohammed Al-Tawil reflects on more than two decades of his career with the organization. Underlining the benefits of being a family-owned company, Tawil explains why Boehringer Ingelheim continues to invest in META,…

Global Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, highlights the achievements of the company’s Rare Humanitarian Program over the last 30 years, bringing treatments to patients in developing countries with lysomal storage disorders who would otherwise not have access. Sibold outlines the persistent obstacles facing people with rare…

Turkey Evren Özlü, General Manager of Turkey and Sub-Saharan Africa at Boehringer Ingelheim, discusses the company’s double-digit growth in the last year, and its leading position as one of the fastest growing pharmaceutical companies in Turkey across Human Pharma and Animal Health. Özlü highlights diabetes and specialty care as the main…

Turkey Polifarma is a Turkish pharma company dedicated to the hospital sector and biosimilars. Its chairman, Ufuk Kumrulu, explains how the company has managed to become a top two company in the hospital segment after Roche, discusses their big bet on biosimilar products through an R&D center and manufacturing plant, and…

Italy An overview of Italy’s pharma, biotech and medtech sectors by number of companies, production value, R&D investment, and number of employees. Made with Visme Infographic Maker   The Italian companies involved in healthcare, split by specialisation, R&D spend, and turnover Made with Visme Infographic Maker   Italy’s regions and their…

China The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in the first half of the year despite pricing squeezes on their mature brands; and why Bayer sees huge growth potential…

Turkey Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer to global organisations, why the well-educated and cost-efficient domestic labour force is so important to the Turkish pharma market’s future,…

Ireland The latest news from Irish pharma, including a big new R&D investment for Abbott; contact lens giant Bausch & Lomb’s EUR 90 million manufacturing investment; and a new report on the danger that confidential pricing agreements pose to sustainable medicine costs in the country.   Abbott confirms new €37.8m R&D…

Global Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for COVID-19 vaccines have evidently been top of their priority lists, other key topics discussed included the potential of data and AI to change the drug approval…

Turkey The president of the Investment Office of the Presidency of the Republic of Turkey, Burak Dağlıoğlu, outlines the country’s current economic situation after posting the second-highest GDP growth among G20 countries in 2020, highlights the crucial role of the life sciences industry during the pandemic and the opportunities available for…

USA In his latest PharmaBoardroom piece, John Singer looks at Biogen’s marketing campaign for its new Alzheimer’s drug, extending and linking the controversy to the grander strategic themes reshaping the ‘drug market’ as a whole, including the impact of the internet on cognitive change, the unmet need for a different premise for…

Switzerland Dr Vincent Forster of Versantis, a Swiss biotech aiming to develop a new generation of liver disease therapeutics and diagnostics, introduces the company’s foundation story, proprietary technology, and future development goals.   As a start-up company, we try to work in a very lean and dynamic way with a small…